Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Innohep vs Warfarin for VTE in Cancer Patients (CATCH)
NCT01130025Phase 3Completed
- Sponsor
- LEO Pharma
- Start
- Aug 2010
- Primary completion
- Apr 2014
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tinzaparin in venous thromboembolism (VTE), sponsored by LEO Pharma. Primary endpoint: Time to first occurrence of recurrent Venous Thromboembolism at 6 months. Started Aug 2010; status: completed.
02
Drugs
tinzaparin
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT01130025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01130025.